Binding Site’s IMMUNOLOGICALS GROUP is pleased to offer a line of highly purified line of TORCH antigens for use in both in-vitro diagnostic (IVD) manufacturing and research applications. As such, the availability of these antigens is certain to benefit the needs of IVD assay manufacturers; clinical, biopharmaceutical, and life science researchers; along with other allied health professionals, as the antigens have been expressly designed for use as an integral component within solid phase ELISA-based immunoassay test procedures.

The TORCH panel is a serologic screening procedure utilized for diagnosing prenatal infections, which may result in birth defects for an infant if the mother should contract any of the disease conditions during the pregnancy. The “TORCH” name of the testing comes from the initial letters of the five disease categories: Toxoplasmosis, Other infections, Rubella, Cytomegalovirus (CMV), and Herpes simplex virus (HSV); where the "other infections" typically includes other viral/bacterial disease states, such as Syphilis, Epstein-Barr Virus, Varicella-Zoster Virus and Human Parvovirus. The antigens are all derived and sourced from infected cells, via culture, which are then treated by heat, detergent, chemical, or UV irradiation to inactivate the pathogenic components. All exhibit high purity levels as a result of either chromatography, cross flow ultra-filtration, ultra-centrifugation, or extraction processes and display the highest degrees of activity and specificity.

In addition, all of the offered antigens demonstrate exceptional lot-to-lot consistency and feature an outstanding shelf life stability claim of ten (10) years from the date of manufacture. The available antigens are offered in a standard packaging formats of 1.0 mg fill vials, with larger, bulk configurations also available.